Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2252W HIGH $0.58
Volume
30.03 K
Value Traded
60.32 K
Short % Float
0.11%
Days to Cover
1.0
+0.72%Week
-23.41%1 Month
-23.01%3 Month
-9.11%6 Month
-81.76%5 Year
-97.31%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
27.85 M
EPS (TTM)
-0.05
P/E Ratio
-
Ent. Value
26.34 M
Total Shares
90.64 M
Float Shares
76.07 M
Insiders
16.08%
Institutions
5.27%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MLSS Catalyst Timeline
Dated clinical, regulatory and corporate events for Milestone Scientific, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Milestone Scientific, Inc.
5Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Past FDA Catalysts and PDUFA Decisions
How MLSS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Milestone Scientific, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every MLSS program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BP4 S.r.l.10% Owner | Sell | -100,000 8,896,765 held | $0.44 | 10/24/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in MLSS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in MLSS for Q2 2026. | ||||
MLSS Institutional Ownership Trends
MLSS Short Interest
Shares sold short, counted twice a month.
0.11%
Short % of Float
of tradable shares sold short
81.2K
Shares Sold Short
-5.9% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
111.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MLSS ranks across every disease it competes in
Competitive Position is a premium feature
See how MLSS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMLSS News
MLSS▼ -2.5%today
Milestone Scientific Provides Major Commercial Growth Update as CompuFlo® Expands Across 30 Million+ Annual Global Epidural Procedures
Milestone Scientific reported significant commercial growth, with a 200% increase in medical segment revenue in Q2 2026. The company has over 500 U.S. leads and is expanding its CompuFlo Epidural System across international markets. With a 2% penetration of the U.S. market representing a potential $33 million revenue opportunity, Milestone is well-positioned for further growth.
Read more →MLSSMilestone Scientific Highlights Building a Scalable Growth Platform for CompuFlo® Medical Business
Milestone Scientific is advancing its CompuFlo medical business by establishing a scalable growth platform. The company is focusing on physician adoption, reimbursement access, and expanding its commercial infrastructure. Positive feedback from the Advisor Program and ongoing clinical studies support the technology's efficacy, while efforts are underway to enhance market presence both domestically and internationally.
Read more →MLSSMilestone Scientific Announces Pain and Spine Specialists and Dr. Sudhir Rao as CompuFlo® Development Partner and Advisor
Milestone Scientific has partnered with Pain and Spine Specialists and Dr. Sudhir Rao to enhance its CompuFlo technology. This collaboration aims to provide real-world clinical feedback, improving the technology's integration into pain management practices. The partnership aligns with Milestone's strategy to achieve Category I CPT status for objective epidural confirmation, enhancing patient care and physician confidence.
Read more →MLSS▲ +11.2%on this news
Milestone Scientific Achieves Debt-Free Balance Sheet Through Debt-to-Equity Conversion by Three Directors
Milestone Scientific Inc. has converted $465,000 in loans into equity, resulting in a debt-free balance sheet. This conversion, executed by three board members, reflects their confidence in the company's future. CEO Eric Hines emphasized that this move strengthens stockholders' equity and aligns directors' interests with shareholders.
Read more →MLSS▼ -10.5%on this news
Milestone Scientific Reports Financial Results for Second Quarter 2026
Milestone Scientific reported a 22% increase in total revenue for Q2 2026, driven by a 231% growth in its medical segment revenue. The company has entered a strategic distribution agreement to enhance CompuFlo access across federal health systems and reaffirmed its outlook for double-digit revenue growth for the year. Despite a decrease in gross margin and ongoing net losses, the company is focused on expanding its market presence and improving operational efficiency.
Read more →MLSSMilestone Scientific Schedules Second Quarter 2026 Financial Results Conference Call
Milestone Scientific Inc. has scheduled a conference call for August 14, 2026, to discuss its financial results for Q2 2026. The call will cover corporate progress and developments. Stakeholders can join via telephone or a live webcast. An audio replay will be available until August 28, 2026.
Read more →MLSSMilestone Scientific Announces Strategic Federal Distribution Partnership with Red One Medical to Expand Commercial Access for the CompuFlo® Epidural System
Milestone Scientific has announced a strategic distribution agreement with Red One Medical to enhance the market reach of its CompuFlo Epidural System within federal healthcare facilities. This partnership aims to leverage Red One's established government contracting capabilities to introduce innovative anesthesia technologies to VA and military healthcare professionals. The collaboration is expected to support product evaluations and broader market penetration, although it does not guarantee contract awards or purchases.
Read more →MLSS▲ +5.3%on this news
Milestone Scientific Launches First Phase of AI Strategy with Pilot Debut of Milo, an AI-enabled Digital Engagement Platform, at ASPN 2026
Milestone Scientific has launched the first phase of its AI strategy with Milo, an AI-enabled digital engagement platform, at the ASPN Annual Conference. Milo is designed to enhance customer engagement and support commercial operations by providing immediate responses to inquiries and facilitating connections with sales and support teams. The platform will be piloted at the conference, with feedback guiding its future development.
Read more →MLSS▲ +9.2%on this news
Milestone Scientific Reports Preliminary 1H 2026 Revenue of ~$5.0M, +9% YoY; Q2 2026 Revenue of ~$2.8M, +21% YoY
Milestone Scientific Inc. reported preliminary revenue of approximately $2.8 million for Q2 2026, marking a 21% increase year-over-year. The company anticipates total revenue of around $5.0 million for the first half of 2026, reflecting a 9% growth compared to the same period in 2025. The medical segment is experiencing significant momentum, with a projected 300% growth compared to Q2 2025. The company will showcase its technology at the upcoming ASPN Conference in Miami Beach.
Read more →MLSSMilestone Scientific Strengthens Board to Support Next Phase of Growth
Milestone Scientific Inc. has announced significant governance changes to bolster its growth strategy. The company appointed Greg Shilling and Kelly Ann Ulto as independent directors, enhancing its Board's expertise. Benedetta I. Casamento has transitioned to Executive Chair, ensuring strategic continuity. Additionally, a restructured agreement with founder Len Osser aims to align governance with shareholder interests.
Read more →MLSSMilestone Scientific Highlights Growing Clinical Adoption and Expanding Physician Acceptance of CompuFlo® Across Epidural, Neuromodulation, and Interventional Pain Procedures
Milestone Scientific Inc. has reported increasing clinical adoption of its CompuFlo Epidural System, backed by new research from the University of Texas Medical Branch. The study indicates that CompuFlo-guided procedures significantly reduce complication rates compared to traditional methods. This technology is gaining traction across various medical applications, enhancing safety and precision in epidural access.
Read more →MLSSMilestone Scientific Reports Financial Results for First Quarter 2026
Milestone Scientific reported financial results for Q1 2026, showing a reduced operating loss and a stable revenue base of $2.16 million. The company highlighted significant growth in its medical segment, with revenue doubling year-over-year. Despite challenges in shipping and a slight decrease in gross profit, management remains optimistic about achieving cash flow breakeven by early 2027.
Read more →MLSS▲ +9.3%on this news
Milestone Scientific Schedules First Quarter 2026 Financial Results and Business Update Conference Call
Milestone Scientific Inc. will hold a conference call on May 14, 2026, to discuss its financial results for Q1 2026 and corporate developments. The call aims to provide insights into the company's progress and future plans. Interested parties can access the call via telephone or a live webcast.
Read more →MLSS▲ +16.3%on this newsshared move
Milestone Scientific Expands CompuFlo® Medical Business with Advisor Program and Growing National Clinical Adoption
Milestone Scientific Inc. has expanded its CompuFlo® medical business through the Advisor Program, which has increased physician utilization and clinical engagement. The company is collaborating with academic institutions to support clinical validation and is enhancing its commercial infrastructure. However, the path to achieving Category I designation remains uncertain, dependent on sustained clinical utilization and peer-reviewed evidence.
Read more →MLSS▲ +8.7%on this news
Milestone Scientific Inc. Completes $2.15 Million Private Placement
Milestone Scientific Inc. has successfully completed a $2.15 million private placement of common stock and warrants, with potential for an additional $2.69 million if cash warrants are exercised. The CEO highlighted the financing as a means to strengthen the company's balance sheet and meet growing demand for its products. Participation from long-term investors underscores confidence in the company's technology and direction.
Read more →MLSS▲ +8.7%on this newsshared move
Milestone Scientific Inc. Completes $2.15 Million Private Placement Strengthens Balance Sheet and Supports Commercial Growth Strategy; Backed by Long-Term Investors Including CEO and Chairman of the Board
Milestone Scientific Inc. (NYSE: MLSS) completed a private placement financing of $2.15 million, enhancing its financial standing. This funding will support the company's growth strategy and consolidate its position in the market for computerized drug delivery instruments. The financing attracted long-term investors, including the CEO, underscoring a robust endorsement of the company's technology. However, the company faces uncertainties related to actual economic conditions and regulatory developments that could impact future performance.
Read more →MLSSMilestone Scientific Reports Financial Results for Fourth Quarter and Full Year 2025
Milestone Scientific reported a modest revenue increase for Q4 2025 and a 4% rise for the full year, driven by international sales. The company anticipates significant growth in 2026, particularly with CompuFlo sales expected to rise by 400%. New leadership has focused on financial discipline and strategic investments to enhance growth prospects.
Read more →MLSS▼ -6.8%on this news
Milestone Scientific Schedules Fourth Quarter and FY 2025 Financial Results and Business Update Conference Call
Milestone Scientific Inc. has scheduled a conference call for April 1, 2026, to discuss its financial results for the fourth quarter and full year ended December 31, 2025. The call will also cover corporate progress and developments. Interested parties can join via telephone or access a webcast of the call.
Read more →MLSSMilestone Scientific Launches CompuFlo® Advisor Program to Accelerate Commercial Adoption and Drive Utilization Growth in Select MAC Jurisdictions; Plans National Expansion
Milestone Scientific has launched the CompuFlo® Advisor Program aimed at boosting commercial adoption and generating clinical data for Medicare reimbursement. Targeting high-volume interventional pain and anesthesia practices, the program will initially focus on select MAC jurisdictions. The initiative includes engaging Key Opinion Leaders and plans for national expansion to enhance revenue visibility.
Read more →MLSSMilestone Scientific Launches The Wand® Ambassador Program to Expand Peer Engagement and Accelerate Market Adoption in Dentistry
Milestone Scientific has launched The Wand® Ambassador Program aimed at enhancing the adoption of its Single Tooth Anesthesia System in dentistry. The program encourages peer-to-peer engagement among dental professionals to share insights and experiences. Following a successful pilot, Milestone plans to expand the program significantly over the next year, anticipating substantial growth in product demonstrations and sales conversions.
Read more →About Milestone Scientific, Inc.
Headquarters220 SOUTH ORANGE AVENUE, LIVINGSTON, NJ, 07039
BIOPHARMAWATCH ELITE PLUS
Trade the next MLSS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime